Chinese Journal of Pharmacovigilance ›› 2023, Vol. 20 ›› Issue (9): 1011-1016.
DOI: 10.19803/j.1672-8629.20220736

Previous Articles     Next Articles

Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children

TAI Jun1, YU Miao2, ZHANG Lin3, LEI Yi3, LIU Junting4, LI Tao4, HUANG Guimin4, CHENG Yijing4, NIE Xiaolu5,6, WANG Qing3,7,*   

  1. 1Otorhinolaryngology Head and Neck Surgery, Children's Hospital, Capital Institute of Pediatrics, Beijing 100020, China;
    2Institute of Systems Engineering, Dalian University of Technology, Dalian Liaoning 116024, China;
    3Research Center for Pharmacovigilance IT and Data Science(PVID), Department of Automation, Tsinghua University, Beijing 100084, China;
    4Child Health Big Data Research Center, Capital Institute of Pediatrics, Beijing 100020, China;
    5Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China;
    6Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100091, China;
    7Pharmacovigilance Research Center for Information Technology and Data Science, Cross-strait Tsinghua Research Institute, Xiamen Fujian 36100, China
  • Received:2022-12-26 Online:2023-09-15 Published:2023-09-14

Abstract: Objective To explore methods of active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children so as to contribute to revelation and mining of the adverse reactions. Methods Using entity recognition technology, adverse reactions in children who used haemocoagulase agkistrodo and were hospitalized at the Capital Institute of Pediatrics between February 25, 2014 and January 8, 2021 were monitored actively and retrospectively. The results of experiments were assessed using three indicators: Precision (P), Recall (R) and F1 value. Results After three rounds of analysis, all the three indicators achieved 100%. Conclusion The application of natural language processing technology can be used to monitor adverse reactions related to haemocoagulase agkistrodon for injection in children.

Key words: haemocoagulase agkistrodon, injection, children, adverse drug reaction, active monitoring, natural language processing

CLC Number: